– Visit Hall 1 U.S. Pavilion, Booth E39, to See Tomorrow’s Medical Technology Today
IRVINE, California, Jan. 28, 2013 /PRNewswire — Masimo (NASDAQ: MASI) returns to Arab Health Jan. 28-31, the world’s longest running healthcare exhibition and congress held each year in Dubai, UAE, to showcase advanced, noninvasive patient monitoring technologies – including breakthrough SET® Measure-Through Motion pulse oximetry and rainbow® Pulse CO-Oximetry® – that are becoming the standard-of-care across the Middle East.
Masimo will demonstrate more than a half-dozen handheld, mobile, OR, ICU, NICU, and bedside technologies. Leading-edge Masimo medical devices on display at Arab Health include:
The 2012 Radical-7® empowers clinicians to improve patient outcomes and reduce the cost of care in multiple ways, such as reducing blood transfusion-related costs and detecting bleeding earlier with noninvasive total hemoglobin (SpHb®), optimizing fluid management with Pleth Variability Index (PVI®), and enabling reliable detection of respiratory depression with acoustic respiration rate (RRa™).
Masimo rainbow® technology allows clinicians to noninvasively measure multiple blood, fluid, and ventilation parameters that previously required invasive or complicated procedures, including SpHb®, oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI®, and RRa™, along with Masimo SET® Measure-Through Motion and low perfusion pulse oximetry for oxygen saturation (SpO2), pulse rate, and perfusion index (PI). With touch, drag, and drop functionality, clinicians can move, expand, or collapse any parameter on screen for real-time analysis. Standard wireless connectivity in the handheld Radical-7® keeps patients connected even when moving from the OR, to critical care areas, to the general floor.
Masimo Patient SafetyNet™
The Masimo Patient SafetyNet™ remote monitoring and clinician notification system combines Masimo rainbow® Pulse CO-Oximetry™ and rainbow® Acoustic Monitoring™ with wireless clinician notifications via pager or smartphone – providing an unmatched level of safety for up to 80 patients on four floors. Patient SafetyNet facilitates early clinical response to preempt sentinel events and avoid unnecessary ICU transfers while helping meet The Joint Commission and Anesthesia Patient Safety Foundation guidelines for patient safety.(1)
SpfO2™ is a new fractional arterial oxygen saturation parameter through the rainbow® Universal ReSposable SuperSensor™, the first noninvasive sensor to provide simultaneous monitoring of SpHb®, SpCO®, SpMet®, SpfO2™, SpOC™, Perfusion Index, PVI®, and Measure-Through Motion and Low Perfusion SpO2 and pulse rate. Until now, pulse oximeters could only measure and display functional oxygen saturation (SpO2), so when patients had elevated carboxyhemoglobin (from carbon monoxide poisoning) and/or elevated methemoglobin (negative reaction to more than 30 common drugs used in hospitals) the displayed functional oxygen saturation overestimated the actual oxygen saturation value. SpfO2™ allows more precise arterial oxygenation assessment and may allow earlier interventions and more timely therapeutic decisions. SpfO2™ is pending U.S. FDA 510(k) clearance.
Also at the Masimo Booth, we will greet visitors with sneak-previews of new technologies for patient care.
Masimo Pronto-7® is a palm-sized handheld device designed for quick and easy noninvasive spot-checking of hemoglobin (SpHb®), SpO2, pulse rate, and perfusion index at the point-of-care. Offering a breakthrough new solution for measuring hemoglobin in less than one minute – without needles, time-consuming laboratory analysis, blood contamination, hazardous medical waste, and patient discomfort associated with traditional blood tests – the Pronto-7® puts the power of noninvasive hemoglobin spot-check measurements into clinician’s hands. With dimensions of just 13 cm x 7.2 cm x 2.5 cm (5.1″ x 2.8″ x 1″) and weight of 296 grams (10.5 ounces), Pronto-7® offers the convenience, speed, and accuracy today’s care providers need to facilitate timely assessment and treatment decisions. And embedded 802.11 b/g and Bluetooth communication capabilities make wireless printing and emailing of test results quick and easy.
“We are honored to showcase and demonstrate our latest cutting-edge, noninvasive patient monitoring innovations at Arab Health,” said Masimo founder and CEO Joe Kiani. “As an increasing number of prestigious hospitals throughout the Middle East adopt Masimo SET® pulse oximetry and rainbow® Pulse CO-Oximetry, we are pleased to deliver our finest patient monitoring technology to this vital area of the world.”
(1) Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. “Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study.” Anesthesiology, February 2010, Vol. 112, Issue 2. Available online here
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve “unsolvable” problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry’s ability to help clinicians detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo’s rainbow® SET® technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SedLine®, a pioneer in the development of innovative brain function monitoring technology and devices. In 2012, Masimo acquired assets of Spire Semiconductor, LLC, maker of advanced light emitting diode (LED) and other advanced component-level technologies; and Phasein AB, a developer and manufacturer of ultra-compact mainstream and sidestream capnography, multigas analyzers, and handheld capnometry solutions. Masimo SET® and Masimo rainbow® SET® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of “Improving Patient Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®.” Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors including: risks related to our assumptions regarding the repeatability of clinical results, risks related to our assumptions that Masimo SpHb accurately tracks and trends Hb changes in all patients, risks related to our assumptions that Masimo Patient SafetyNet helps hospitals avoid preventable deaths and injuries associated with failure to rescue events for all monitored patients, risks related to SpfO2™ and SuperSensors represent an innovative solution to more accurately measure blood oxygenation and hemoglobin, which could allow clinicians to make earlier interventions or better therapeutic decisions, risks related to our belief that the Pronto-7 enables quick and easy noninvasive spot-checking of hemoglobin (SpHb®), SpO2, pulse rate, and perfusion index at the point-of-care for all patients, as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC“), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Phone: (949) 297-7434
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.